Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Colon cancer (CC) pathological staging fails to accurately predict recurrence, and to date, no gene expression signature has proven reliable for prognosis stratification in clinical practice, perhaps because CC is a heterogeneous disease. The aim of this study was to establish a comprehensive molecular classification of CC based on mRNA expression profile analyses. METHODS AND FINDINGS: Fresh-frozen primary tumor samples from a large multicenter cohort of 750 patients with stage I to IV CC who underwent surgery between 1987 and 2007 in seven centers were characterized for common DNA alterations, including BRAF, KRAS, and TP53 mutations, CpG island methylator phenotype, mismatch repair status, and chromosomal instability status, and were screened with whole genome and transcriptome arrays. 566 samples fulfilled RNA quality requirements. Unsupervised consensus hierarchical clustering applied to gene expression data from a discovery subset of 443 CC samples identified six molecular subtypes. These subtypes were associated with distinct clinicopathological characteristics, molecular alterations, specific enrichments of supervised gene expression signatures (stem cell phenotype-like, normal-like, serrated CC phenotype-like), and deregulated signaling pathways. Based on their main biological characteristics, we distinguished a deficient mismatch repair subtype, a KRAS mutant subtype, a cancer stem cell subtype, and three chromosomal instability subtypes, including one associated with down-regulated immune pathways, one with up-regulation of the Wnt pathway, and one displaying a normal-like gene expression profile. The classification was validated in the remaining 123 samples plus an independent set of 1,058 CC samples, including eight public datasets. Furthermore, prognosis was analyzed in the subset of stage II-III CC samples. The subtypes C4 and C6, but not the subtypes C1, C2, C3, and C5, were independently associated with shorter relapse-free survival, even after adjusting for age, sex, stage, and the emerging prognostic classifier Oncotype DX Colon Cancer Assay recurrence score (hazard ratio 1.5, 95% CI 1.1-2.1, p = 0.0097). However, a limitation of this study is that information on tumor grade and number of nodes examined was not available. CONCLUSIONS: We describe the first, to our knowledge, robust transcriptome-based classification of CC that improves the current disease stratification based on clinicopathological variables and common DNA markers. The biological relevance of these subtypes is illustrated by significant differences in prognosis. This analysis provides possibilities for improving prognostic models and therapeutic strategies. In conclusion, we report a new classification of CC into six molecular subtypes that arise through distinct biological pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Summary of the main characteristics of the six subtypes. Symbols correspond to the relative frequency within the subtype (o: very low frequencies [∼0%]; +++: very high frequencies; +/++: intermediate frequencies), and arrows indicate significant enrichment of subtype up- and down-regulated genes in most of the pathways of the given category. EMT, epithelial–mesenchymal transition; SC, stem cell; Wnt pw, Wnt pathway.](https://figures.cochat.ai/paper-figures/d9e6ea3312ee4d83b17b55c403c90fdb/gene-expression-classification-of-colon-cancer-into-molecular-subtypes-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Again, the MEKi bypass resistance was strongly correlated with the SRC activation/dasatinib sensitivity, the EMT-like stemness and the CMS4 subtype (see Fig. 6 and Fig. 7 as well as Additional File 3_Fig S5 and Fig S6).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar results were seen in Marisa 458 CMS1-4 CRC tumors (Fig. 8d).”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Edge, S. B., & Compton, C. C. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0985-4 · Cited by 9,029
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
Monti, S., Tamayo, P., Mesirov, J., & Golub, T. (2003) · Machine Learning · doi:10.1023/a:1023949509487 · Cited by 2,116 · cited 1×
“To obtain a robust classification, we used a consensus unsupervised approach [22] implemented in the R package ConsensusClusterPlus.”
MethodWeisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Research works printed but not linked: 1
- American Joint Committee on Cancer (1997) AJCC cancer staging manual, 5th edition. Philadelphia: Lippincott-Raven.
Cited by
Items 501–600 of 1,001
Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07316-z · Cited by 27
TFF2–CXCR4 Axis Is Associated with BRAF V600E Colon Cancer
Gala, M. K., Austin, T. R., Ogino, S., & Chan, A. T. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0444 · Cited by 27
Zhu, S., Wu, Q., Zhang, B., Wei, H., Li, B., Shi, W., Fang, M., Zhu, S., Wang, L., Zhou, Y. L., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106757 · Cited by 28
Serrated neoplasia in the colorectum: gut microbiota and molecular pathways
Kang, X., Zhang, R., Kwong, T. N. Y., Lui, R. N.-S., Wu, W. K. K., Sung, J. J. �., Yu, J. Q., & Wong, S. H. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1863135 · Cited by 27
Integrated multiplex network based approach for hub gene identification in oral cancer
Mahapatra, S., Bhuyan, R., Das, J., & Swarnkar, T. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07418 · Cited by 27
Liang, Y., Wu, X., Su, Q., Liu, Y., & Xiao, H. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s321852 · Cited by 27
Amar, D. B., Thoinet, K., Villalard, B., Imbaud, O., Costechareyre, C., Jarrosson, L., Reynaud, F., Ducassou, J. N., Couté, Y., Brunet, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30237-3 · Cited by 27
Ying, Y., Wang, M., Chen, Y., Li, M., Ma, C., Zhang, J., Huang, X., Jia, M., Zeng, J., Wang, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120633119 · Cited by 27
Du, X., Qi, H., Ji, W., Li, P., Hua, R., Wen-liang, H., & Qi, F. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/9408839 · Cited by 27
Yang, W., Lu, S., Peng, L., Zhang, Z., Zhang, Y., Guo, D., Ma, F., Hua, Y., & Chen, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1085038 · Cited by 27
Zhang, E., Ding, C., Li, S., Aikemu, B., Zhou, X., Fan, X., Sun, J. P., Yang, X. Y., & Zheng, M. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02892-z · Cited by 27
Targeting intratumor heterogeneity suppresses colorectal cancer chemoresistance and metastasis
Chao, S., Zhang, F., Yan, H., Wang, L., Zhang, L., Wang, Z., Xue, R., Wang, L., Wu, Z., Jiang, B., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256416 · Cited by 27
Reimers, M. S., Kuppen, P. J. K., Lee, M., Lopatin, M., Tezcan, H., Putter, H., Clark-Langone, K. M., Liefers, G., Shak, S., & van de Velde, C. J. �. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju269 · Cited by 27
A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer
Salvucci, M., Würstle, M. L., Morgan, C., Curry, S., Cremona, M., Lindner, A. U., Bacon, O., Resler, A. J., Murphy, Á. C., O’Byrne, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1084 · Cited by 27
Self-citationStewart, P., Richman, S. D., Maughan, T., Lawler, M., Dunne, P. D., & Salto‐Tellez, M. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.05.005 · Cited by 28
Xie, Y., Liu, Y., Li, Q., & Chen, J. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4328 · Cited by 27
Upregulated NLGN1 predicts poor survival in colorectal cancer
Yu, Q., Wang, X., Yang, Y., Chi, P., Huang, J., Qiu, S., Zheng, X. M., & Chen, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08621-x · Cited by 27
(2022) · PubMed Central · Cited by 26
Gao, Q., Yang, L., Ye, S., Mai, M., Liu, Y., Jiang, X., Feng, X., & Yang, Z. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv0766 · Cited by 26
Tissue-location-specific transcription programs drive tumor dependencies in colon cancer
Yang, L., Tu, L., Bisht, S., Mao, Y., Petkovich, D. A., Thursby, S.-J., Liang, J., Patel, N., Yen, R.-W. C., Largent, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45605-4 · Cited by 26
Gene Expression Signatures Based on Variability can Robustly Predict Tumor Progression and Prognosis
Dinalankara, W., & Bravo, H. C. (2015) · Cancer Informatics · doi:10.4137/cin.s23862 · Cited by 26
Liu, D. (2016) · FEBS Journal · doi:10.1111/febs.13798 · Cited by 26
Alwers, E., Bläker, H., Walter, V., Jansen, L., Kloor, M., Arnold, A., Sieber‐Frank, J., Herpel, E., Tagscherer, K. E., Roth, W., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5842-7 · Cited by 26
Yang, X., Lei, P., Huang, L., Tang, X., Wei, B., & Wei, H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.58876 · Cited by 26
Hu, F., Wang, J., Zhang, M., Wang, S., Zhao, L., Yang, H., Wu, J., & Cui, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.758776 · Cited by 27
Guo, L., Yang, G., Kang, Y., Li, S., Duan, R., Shen, L., Jiang, W., Qian, B., Yin, Z., & Liang, T. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00418 · Cited by 25
Zhang, M., Wang, H., Li, H., Zhou, Y., Peng, R., Liu, J., & Zhao, Q. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5574 · Cited by 25
Liu, J., Yu, F., Tan, Y., Huo, J.-P., Liu, Z., Wang, X., & Li, J. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4118 · Cited by 25
Wang, L., Liu, D., Liu, S., Liao, T., Jiao, Y., Jiang, X., Wang, Y., Chen, Y., Ma, H., & Cai, H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101435 · Cited by 25
Monsma, D. J., Cherba, D., Richardson, P. J., Vance, S. M., Rangarajan, S. V., Dylewski, D., Eugster, E., Scott, S. B., Beuschel, N. L., Davidson, P. J., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25039 · Cited by 25
MicroRNA-215 is a potential prognostic marker for cervical cancer
Liang, H. L., Li, Y., Luo, R., & Shen, F. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1260-x · Cited by 25
c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells
Pekarčíková, L., Knopfová, L., Beneš, P., & Šmarda, J. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.04.007 · Cited by 25
Bianchi, A. S., Siena, S., Tonini, G., Bardelli, A., & Santini, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.10.006 · Cited by 25
Forsythe, N., Refaat, A., Javadi, A., Khawaja, H. A., Weir, J.-A., Emam, H., Allen, W. L., Burkamp, F., Popovici, V. C., Jithesh, P. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0603 · Cited by 26
Shimoni, Y. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006026 · Cited by 25
Makondi, P. T., Wei, P., Huang, C., & Chang, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211968 · Cited by 25
SK4 oncochannels regulate calcium entry and promote cell migration in KRAS-mutated colorectal cancer
Ibrahim, S., Chaigne, J., Dakik, H., Fourbon, Y., Corset, L., Lecomte, T., Raoul, W., & Guéguinou, M. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102384 · Cited by 25
Current controversies in the management of metastatic colorectal cancer
Vera, R., Alonso, V., Gallego-Plazas, J., González‐Flores, E., Guillén‐Ponce, C., Pericay, C., Rivera, F., Safont, M. J., & Valladares‐Ayerbes, M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2808-6 · Cited by 25
Bastin, J., Sroussi, M., Nemazanyy, I., Laurent-Puig, P., Mouillet-Richard, S., & Djouadi, F. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04341-x · Cited by 24
Self-citationvan Pelt, G. W., Hansen, T. F., Bastiaannet, E., Frifeldt, S. K., van Krieken, J. H. J., AEM Tollenaar, R., Sorensen, F. B., & Mesker, W. E. (2016) · Journal of Medical & Surgical Pathology · doi:10.4172/2472-4971.1000116 · Cited by 24
Barry, G. S., Cheang, M. C. U., Chang, H. L., & Kennecke, H. F. (2016) · Oncotarget · doi:10.18632/oncotarget.8006 · Cited by 24
Overexpression of MAGT1 is associated with aggressiveness and poor prognosis of colorectal cancer
Zheng, K., Yang, Q., Xie, L., Qiu, Z., Huang, Y., Lin, Y., Tu, L., & Cui, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10710 · Cited by 24
Zhou, R., Xie, F., Liu, K., Zhou, X., Chen, X., Chen, J., Xi, S., Huang, Z., & Rong, X. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01290-y · Cited by 24
Hou, Y., Zhang, R., Zong, J., Wang, W., Zhou, M., Yan, Z., Li, T., Gan, W., Lv, S., Zeng, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.892512 · Cited by 24
The immune phenotypes and different immune escape mechanisms in colorectal cancer
Mao, Y., Xu, Y., Jiang, C., Chang, W., Lv, Y., Zheng, P., Zhang, Z., Li, Z., Lin, Q., Tang, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968089 · Cited by 24
Robertis, M. D., Greco, M. R., Cardone, R. A., Mazza, T., Marzano, F., Mehterov, N. H., Kazakova, M., Belev, N., Tullo, A., Pesole, G., et al. (2022) · Cells · doi:10.3390/cells11223568 · Cited by 24
Bhuia, M. S., Chowdhury, R., Afroz, M., Akbor, M. S., Hasan, M. S. A., Ferdous, J., Hasan, R., de Alencar, M. V. O. B., Mubarak, M. S., & Islam, M. T. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401904 · Cited by 24
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 24
Alajez, N. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167455 · Cited by 24
Building personalized treatment plans for early-stage colorectal cancer patients
Lin, H., Wei, N.-C., Chou, T., Lin, C., Lan, Y.-T., Chang, S.-C., Wang, H., Yang, S., Chen, W.-S., Lin, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14638 · Cited by 24
Hope4Genes: a Hopfield-like class prediction algorithm for transcriptomic data
Cantini, L., & Caselle, M. (2019) · Scientific Reports · doi:10.1038/s41598-018-36744-y · Cited by 24
Dho, S. H., Cho, E. J., Lee, J. H., Lee, S., Jung, S. H., Kim, L. K., & Lim, J. Y. (2019) · Oncology Reports · doi:10.3892/or.2019.7337 · Cited by 24
Prognostic and predictive values of CXCL10 in colorectal cancer
Chen, J., Chen, Q.-L., Wang, W.-H., Chen, X., Hu, X., Liang, Z., Cao, Y., Cao, Y., & Su, S.-B. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02299-6 · Cited by 24
Canlı, S. D., Seza, E. G., Sheraj, I., Gömceli, İ., Turhan, N., Carberry, S., Prehn, J. H. M., Gure, A. O., & Banerjee, S. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa072 · Cited by 24
Identification of hub genes associated with neutrophils infiltration in colorectal cancer
Su, H., Cai, T., Zhang, S., Yan, X., Zhou, L., He, Z., Xue, P., Li, J., Zheng, M., Yang, X., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16414 · Cited by 24
Lampis, A., Hahne, J. C., Gasparini, P., Cascione, L., Hedayat, S., Vlachogiannis, G., Murgia, C., Fontana, E., Edwards, J., Horgan, P. G., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00820-0 · Cited by 24
Mazzeschi, M., Sgarzi, M., Romaniello, D., Gelfo, V., Cavallo, C., Ambrosi, F., Morselli, A., Miano, C., Laprovitera, N., Girone, C., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02309-1 · Cited by 24
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells
Chauvin, A., Bergeron, D., Vencic, J., Lévesque, D., Paquette, B., Scott, M. S., & Boisvert, F. (2022) · BMC Cancer · doi:10.1186/s12885-022-09417-3 · Cited by 24
Dunne, P. D., O’Reilly, P. G., Coleman, H. G., Gray, R. T., Longley, D. B., Johnston, P. G., Salto‐Tellez, M., Lawler, M., & McArt, D. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9126 · Cited by 25
Trumpi, K., Frenkel, N. C., Peters, T., Korthagen, N. M., Jongen, J. M. J., Raats, D., van Grevenstein, H. M. U., Backes, Y., Moons, L. M. G., Laclé, M. M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24626 · Cited by 24
Shen, P.-W., Chou, Y.-M., Li, C.-L., Liao, E.-C., Huang, H.-S., Yin, C.-H., Chen, C.-L., & Yu, S.-J. (2021) · Oncology Letters · doi:10.3892/ol.2021.13029 · Cited by 23
“Despite medical advancements, colon cancer remains the fifth most common type of cancer and is the fourth‐leading cause of cancer‐associated mortality worldwide (2).”
BackgroundWang, T., Chen, Z., Wang, W., Wang, H., & Li, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1556386 · Cited by 23
Guo, Z., Feng, H., Jia, W., Zhang, T., Chen, M., Xu, Z., Zheng, F., Huang, C., Li, Z., Liu, K., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002568 · Cited by 23
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 23
LIN, Q. S., Luo, L., & Wang, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644956 · Cited by 23
Rao, J., Li, W., & Chen, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.766503 · Cited by 23
Ito, M., Nakano, M., Ariyama, H., Yamaguchi, T., Tanaka, R., Semba, Y., Sugio, T., Miyawaki, K., Kikushige, Y., Mizuno, S., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215597 · Cited by 23
Liang, W., Zuo, J., Liu, M., Su, Y., Guo, B., Hou, J., Xing, Q., Peng, Y., Fang, L., Cao, Y., et al. (2022) · The FASEB Journal · doi:10.1096/fj.202201181r · Cited by 23
Pharmacologic inhibition of IL11/STAT3 signaling increases MHC-I expression and T cell infiltration
Xiong, W., Chen, Y., Zhang, C., Li, J., Huang, H., Zhu, Y. H., Deng, G., Cheng, J., Lin, Y., Shi, Z., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04079-6 · Cited by 23
Leonard, N. A., Corry, S. M., Reidy, E., Egan, H., O’Malley, G., Thompson, K., McDermott, E. A., O’Neill, A., Zakaria, N., Egan, L. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110701 · Cited by 23
A transcriptomic insight into the impacts of mast cells in lung, breast, and colon cancers
Ko, E.-A., Sanders, K. M., & Zhou, T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1360457 · Cited by 23
Peyravian, N., Larki, P., Gharib, E., Mojarad, E. N., Anaraki, F., Young, C., McClellan, J. A., Bonab, M. A., Asadzadeh‐Aghdaei, H., & Zali, M. R. (2018) · Biomedicines · doi:10.3390/biomedicines6010027 · Cited by 23
Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 25
Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer
Ruan, G., Gong, Y., Liao, X., Wang, S., Huang, W., Wang, X., Zhu, G., Liao, C., & Gao, F. (2019) · Oncology Reports · doi:10.3892/or.2019.7326 · Cited by 23
NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer
O'Cathail, S. M., Wu, C., Lewis, A., Holmes, C. C., Hawkins, M., & Maughan, T. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.08.006 · Cited by 23
Yao, X., Tian, J. Y., Wang, T., Gu, C., Chen, X., Chen, F., Feng, H., Zhao, H., Chen, D., & Ma, W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.694702 · Cited by 23
Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09344-3 · Cited by 22
“by two independent CRC tumor datasets We validated the findings from > 2000 Moffitt CRC tumors using two independent, publicly-available CRC human datasets (Marisa 585 CRCs [23] and TCGA 677 CRCs [47], see METHODS).”
MethodInfluentialO’Neill, A., Zakaria, N., Egan, H., Corry, S. M., Bull, C., Leonard, N. A., O'Meara, C., Howard, L., Walsh, A., Reidy, E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012491 · Cited by 22
Treatment Individualization in Colorectal Cancer
van Geel, R. M. J. M., Beijnen, J. H., Bernards, R., & Schellens, J. H. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0288-z · Cited by 22
Aberrantly Methylated and Expressed Genes as Prognostic Epigenetic Biomarkers for Colon Cancer
Wu, Y., Wan, X., Jia, G., Xu, Z., Tao, Y., Song, Z., & Du, T. (2020) · DNA and Cell Biology · doi:10.1089/dna.2020.5591 · Cited by 23
Zhong, M., Duan, X., Nijiati, M., Qi, H., Xu, D., Cai, D., Li, C., Huang, Z.-P., Zhu, Q., Gao, F., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03788-8 · Cited by 23
Li, X., Lei, J., Shi, Y., Peng, Z., Gong, M., & Shu, X. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673277243231108071620 · Cited by 22
Jary, M., Lecomte, T., Bouché, O., Kim, S. C. H., Dobi, E., Queiroz, L., Ghiringhelli, F., Etienne, H., Léger, J., Godet, Y., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30367 · Cited by 22
IMP1 3′ UTR shortening enhances metastatic burden in colorectal cancer
Andres, S. F., Williams, K. N., Plesset, J. B., Headd, J. J., Mizuno, R., Chatterji, P., Lento, A., Klein–Szanto, A. J., Mick, R., Hamilton, K. E., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy153 · Cited by 22
Zheng, H., Bai, Y., Wang, J., Chen, S., Zhang, J., Zhu, J., Liu, Y., & Wang, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.649363 · Cited by 23
Shi, J., Bao, M., Wang, W.-F., Wu, X., Li, Y., Changdong, Z., & Liu, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.722807 · Cited by 22
Ren, J., Wang, C., Ye, M., Yuan, Q., Wang, C., & Feng, X. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220404125228 · Cited by 22
He, L., Deng, H., & C.WANG, X. (2016) · Neoplasma · doi:10.4149/neo_2017_108 · Cited by 22
Human papillomaviruses in colorectal cancers: A case-control study in western patients
Vuitton, L., Jaillet, C., Jacquin, É., Monnien, F., Heberle, M., Mihai, M. I., Lassabe, C., Raffoul, J., Puyraveau, M., Lakkis, Z., et al. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.11.003 · Cited by 22
Prognostic value of the PrP C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype
Ghazi, A., Le Corre, D., Pilati, C., Taieb, J., Aparicio, T., Didelot, A., Dedhar, S., Mulot, C., Le Malicot, K., Djouadi, F., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1940674 · Cited by 21
“GSEA(9) was performed on the GSE39582 dataset.(10) This cohort is composed of n = 91 CMS1, n = 232 CMS2, n = 69 CMS3, n = 127 CMS4 n = 47 unclassified and n = 19 non tumor”
MethodSelf-citationAnalysis of multi-omics differences in left-side and right-side colon cancer
Huang, Y., Duanmu, J., Liu, Y., Yan, M., Li, T., & Jiang, Q. (2021) · PeerJ · doi:10.7717/peerj.11433 · Cited by 21
Piecyk, M., Triki, M., Laval, P., Duret, C., Fauvre, J., Cussonneau, L., Machon, C., Guitton, J., Rama, N., Gibert, B., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13491 · Cited by 21
Chen, Z., Li, Q., Lin, Y., Lin, S., Gao, J., & Chen, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-37300-z · Cited by 21
Yin, Y., Xiao-jie, Y., Cheng, Z., Wang, H., Lei, J., Wang, D., Wang, P., Li, B., Mi, J., & Yuan, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371584 · Cited by 21
A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues
de Back, T. R., Wu, T., Schafrat, P. J. M., ten Hoorn, S., Tan, M., He, L., van Hooff, S. R., Köster, J., Nijman, L. E., Vink, G. R., et al. (2024) · Life Science Alliance · doi:10.26508/lsa.202402730 · Cited by 21
Chowdhury, S., Xiu, J., Ribeiro, J. R., Nicolaides, T. P., Zhang, J., Korn, W. M., Poorman, K. A., Lenz, H., Marshall, J. L., Oberley, M. J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02826-0 · Cited by 21
Zhang, T., Huang, T., & Wang, R. (2018) · Oncology Letters · doi:10.3892/ol.2018.8860 · Cited by 21
Eilertsen, I. A., Moosavi, S. H., Strømme, J. M., Nesbakken, A., Johannessen, B., Lothe, R. A., & Sveen, A. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.040 · Cited by 21
Abnormal expression of ABCD3 is an independent prognostic factor for colorectal cancer
Zhang, Y., Zhang, Y., Wang, J., Yang, J., & Yang, G. (2020) · Oncology Letters · doi:10.3892/ol.2020.11463 · Cited by 21
Clinical Significance of a Gene Signature Generated from Tumor Budding Grade in Colon Cancer
Shinto, E., Yoshida, Y., Kajiwara, Y., Okamoto, K., Mochizuki, S., Yamadera, M., Shiraishi, T., Nagata, K., Tsuda, H., Hase, K., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08498-3 · Cited by 21
Metadata
- Authors
- Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., Kirzin, S., Chazal, M., Fléjou, J.-F., Benchimol, D., Berger, A., Lagarde, A., Pencreach, E., Piard, F., Elias, D., Parc, Y., Olschwang, S., Milano, G., Laurent-Puig, P., & Boige, V.
- Affiliations
- Inserm (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- La Ligue Contre le Cancer (FR)
- Université Toulouse III - Paul Sabatier (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Hôpital Européen Georges-Pompidou (FR)
- CHU Dijon Bourgogne (FR)
- Institut Gustave Roussy (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-21
- Volume
- 10
- Issue
- 5
- Pages
- e1001453
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3660251
- OpenAlex
- W2154941270
- Cited by
- 1,507
- References
- 40
- Citations by year
- 2026: 84 · 2025: 111 · 2024: 108 · 2023: 142 · 2022: 145 · 2021: 194 · 2020: 131 · 2019: 126 · 2018: 131 · 2017: 108 · 2016: 90 · 2015: 74 · 2014: 53 · 2013: 8
- FWCI
- 56.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Association for Cancer Research
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- colon cancer, molecular subtypes, gene expression signatures, mismatch repair deficiency, chromosomal instability, KRAS mutation, BRAF mutation, TP53 mutation, CpG island methylator phenotype, Wnt signaling, relapse-free survival, prognosis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Colonic Neoplasms, Female, France, Genetic Testing, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Phenotype, Predictive Value of Tests, Prognosis, Risk Factors, RNA, Messenger, Time Factors, Biomarkers, Tumor, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Multivariate Analysis, Cluster Analysis, Chi-Square Distribution, Logistic Models, Proportional Hazards Models, Risk Assessment, Genetic Predisposition to Disease, Gene Expression Profiling, Kaplan-Meier Estimate, Young Adult, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.